CG Invites Co., Ltd. Logo

CG Invites Co., Ltd.

A biopharmaceutical company specializing in digital genomics and personalized medicine.

083790 | KO

Overview

Corporate Details

ISIN(s):
KR7083790006
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 38 마곡동, 강서구

Description

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-31 00:00
기업설명회(IR)개최
Korean HTML 6.8 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.8 MB
2025-08-14 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 34.7 KB
2025-08-08 00:00
[기재정정]사업보고서 (2024.12)
Korean HTML 2.7 MB
2025-07-25 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean HTML 16.5 KB
2025-07-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.3 KB
2025-07-10 00:00
소송등의판결ㆍ결정 (신주발행 무효-취하)
Korean HTML 5.3 KB
2025-07-10 00:00
소속부변경
Korean HTML 3.6 KB
2025-07-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 38.0 KB
2025-07-01 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean HTML 14.1 KB
2025-07-01 00:00
소속부변경
Korean HTML 3.6 KB
2025-06-05 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 134.5 KB
2025-06-05 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 28.6 KB
2025-06-05 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 29.4 KB
2025-06-05 00:00
기업설명회(IR)개최
Korean HTML 6.8 KB

Automate Your Workflow. Get a real-time feed of all CG Invites Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CG Invites Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CG Invites Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures biologic medicines, including biosimilars and novel drugs.
South Korea
007460
Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
South Korea
293780
Aptamer Sciences Inc Logo
Clinical-stage company developing aptamer-based therapeutics for oncology.
South Korea
291650
Aptorum Group Ltd Logo
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Pharmaceutical company developing oral film medicines for CNS and allergic reactions.
United States of America
AQST
Arbutus Biopharma Corp Logo
Clinical-stage biopharma company developing a functional cure for chronic Hepatitis B.
United States of America
ABUS
Arcellx, Inc. Logo
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharmaceutical and nutraceutical products from marine membrane lipids.
Norway
ABS
ArcticZymes Technologies Logo
Develops and manufactures novel recombinant enzymes from Arctic marine organisms.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
A commercial-stage mRNA medicines company focused on rare and infectious diseases.
United States of America
ARCT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.